
Opinion|Videos|December 20, 2024
Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases
Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Anti-VEGF treatments have been available for age-related macular degeneration and diabetic macular edema for over a decade. Can you discuss how they have impacted patient outcomes and what barriers remain to achieving optimal results?
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
2
FLORetina 2025: New horizons in research and risk management for ROP
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
5














































